Details

Autor(en) / Beteiligte

• van Riel, Annelieke C.M.J
• Schuuring, Mark J
• van Hessen, Irene D
• Zwinderman, Aielko H
• Cozijnsen, Luc
• Reichert, Constant L.A
• Hoorntje, Jan C.A
• Wagenaar, Lodewijk J
• Post, Marco C
• van Dijk, Arie P.J
• Hoendermis, Elke S
• Mulder, Barbara J.M
• Bouma, Berto J

Titel

Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification

Ist Teil von

• International journal of cardiology, 2014-06, Vol.174 (2), p.299-305

Ort / Verlag

Shannon: Elsevier Ireland Ltd

Erscheinungsjahr

2014

Quelle

Elsevier ScienceDirect Journals

Beschreibungen/Notizen

• Abstract Background The aging congenital heart disease (CHD) population is prone to develop a variety of sequelae, including pulmonary arterial hypertension (PAH). Previous prevalence estimates are limited in applicability due to the use of tertiary centers, or database encoding only. We aimed to investigate the contemporary prevalence of PAH in adult CHD patients, using a nationwide population. Methods A cross-sectional study was performed, using the population-based Dutch CONgenital CORvitia (CONCOR) registry. All patients born with a systemic-to-pulmonary shunt, thereby at risk of developing PAH, were identified. From this cohort, a random sample was obtained and carefully reviewed. Results Of 12,624 registered adults with CHD alive in 2011, 5,487 (44%) were at risk of PAH. The random sample consisted of 1,814 patients (mean age 40 ± 15 years) and 135 PAH cases were observed. PAH prevalence in patients born with a systemic-to-pulmonary shunt was 7.4%. The prevalence of PAH after corrective cardiac surgery was remarkably high (5.7%). Furthermore, PAH prevalence increased with age, from 2.5% under 30 years until 35% in the eldest. PAH prevalence in the entire CHD population was 3.2%. Based on 3000 per million adult CHD patients in the general population, we can assume that PAH-CHD is present in 100 per million. Conclusions This new approach using a nationwide CHD population reports a PAH prevalence of 3.2% in CHD patients, and 100 per million in the general adult population. Especially in patients after shunt closure and the elderly, physicians should be aware of PAH-CHD, to provide optimal therapeutic and clinical care.